Abstract

BackgroundMelanoma is the most lethal type of skin cancer. Since chemoresistance is a significant barrier, identification of regulators affecting chemosensitivity is necessary in order to create new forms of intervention. Prohibitin 1 (PHB1) can act as anti-apoptotic or tumor suppressor molecule, depending on its subcellular localization. Our recent data shown that accumulation of PHB1 protects melanoma cells from chemotherapy-induced cell death. Lacking of post-transcriptional regulation of PHB1 could explain this accumulation. Interestingly, most of melanoma patients have down-regulation of microRNA-195. Here, we investigate the role of miR-195, its impact on PHB1 expression, and on chemosensitivity in melanoma cells.MethodsTCGA-RNAseq data obtained from 341 melanoma patient samples as well as a panel of melanoma cell lines were used in an expression correlation analysis between PHB1 and predicted miRNAs. miR-195 impact on PHB1 mRNA and protein levels and relevance of this regulation were investigated in UACC-62 and SK-MEL-5 melanoma lines by RT-qPCR and western blot, luciferase reporter and genetic rescue experiments. Cell proliferation, cell-cycle analysis and caspase 3/7 assay were performed to investigate the potential action of miR-195 as chemosensitizer in melanoma cells treated with cisplatin and temozolomide.ResultsAnalysis of the TCGA-RNAseq revealed a significant negative correlation (Pearson) between miR-195 and PHB1 expression. Moreover, RT-qPCR data showed that miR-195 is down-regulated while PHB1 is up-regulated in a collection of melanoma cells. We demonstrated that miR-195 regulates PHB1 directly by RT-qPCR and western blot in melanoma cells and luciferase assays. To establish PHB1 as a relevant target of miR-195, we conducted rescue experiments in which we showed that PHB1 transgenic expression could antagonize the suppressive effect miR-195 on the proliferation of melanoma cells. Finally, transfection experiments combined with drug treatments performed in the UACC-62 and SK-MEL-5 melanoma cells corroborated miR-195 as potential anti-proliferative agent, with potential impact in sensitization of melanoma cell death.ConclusionsThis study support the role of miR-195 as anti-proliferative miRNA via targeting of PHB1 in melanoma cells.

Highlights

  • Melanoma is the most lethal type of skin cancer

  • This study support the role of miR-195 as anti-proliferative miRNA via targeting of Prohibitin 1 (PHB1) in melanoma cells

  • PHB1 expression is negatively correlated with miRNA-195 expression To define regulators that could influence the expression of PHB1 in melanoma, we looked into the miRanda Database and identified 28 miRNAs with putative sites in the PHB1 3’UTR region

Read more

Summary

Introduction

Melanoma is the most lethal type of skin cancer. Melanoma is the most aggressive and lethal type of skin cancer. Unresectable stage III, IV and recurrent melanomas are treated with chemotherapy, targeted therapy or immunotherapy [1]. Cutaneous melanoma is classified into four subtypes based on the status of the most significant mutated genes: BRAF, RAS, NF1, and Triple-WT (wild-type) [2]. Immunotherapy has been used to treat metastatic melanoma with significant improvement in overall survival and progression-free survival compared to chemotherapy [4]. Therapeutic strategies using conventional chemotherapy, alone or in combination with other therapies, are under investigation to improve the efficacy of treatment of metastatic melanoma [5, 6]. Better knowledge of the molecular mechanisms and signaling pathways associated with chemoresistance in melanoma is necessary to design novel therapeutic strategies

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.